Amy Moore: PD-1/VEGF combos are a strategy to watch in lung cancer
Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a post on LinkedIn about a recent paper by Keiju Aokage et al. published in Clinical Cancer Research:
“As the field moves to tackle early-stage lung cancer, PD-1/VEGF combos are a strategy to watch in their various forms. The addition of angiogenesis inhibitors may enhance the activity of immune checkpoint inhibitors.”
Authors: Keiju Aokage, Shohei Koyama, Shogo Kumagai, Norihiko Ikeda, Masahiro Tsuboi et al.
More posts featuring Amy Moore.
Dr. Amy C. Moore is the Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation. She previously served as the Director of Science and Research at the Addario Lung Cancer Medical Institute (ALCMI).
She has published peer-reviewed papers on virology, cancer, and biomarker testing in NSCLC. Dr. Moore is also an expert on COVID-19’s impact on lung cancer and serves on several advisory boards.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023